Drifting Away from Informed Consent in the Era of Personalized Medicine
By Erik Parens,
The Hastings Center Report
| 07. 23. 2015
The price of sequencing all the DNA in a person's genome is falling
so fast that, according to one biotech leader, soon it won't cost
much more than flushing a toilet.1
Getting all that genomic data at an ever-lower cost excites the
imaginations not only of biotech investors and researchers but also of
the President and many members of Congress.2 They envision the data ushering in an age of “personalized medicine,” where medical care is tailored to persons’ genomes.
Since the 1990 start of the project to map the human genome,
sequencing advocates have been predicting our imminent arrival in the
Promised Land of Health. In 2000, when Francis Collins shared in
announcing the completion of a first draft of a human genome sequence,
he said that we now possessed the “book of life.”3
Soon, he foresaw, we would find single misspelled words in that book
that would be the keys to diagnosing, treating, and preventing both
common and rare diseases.
Since 2000, researchers have actually achieved some stunning
successes in personalized medicine, including making some definitive...
Related Articles
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Risa Cromer, The Conversation | 07.17.2026
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...
Media coverage of recent developments in embryo gene editing might seem to suggest that gene-edited babies are close to becoming a reality. As tech billionaires eager to profit off of techno-eugenics invest in “designer baby” technologies, attempts to normalize heritable genome editing – which remains unsafe and raises significant ethical and societal concerns – are especially dangerous. It’s worth taking a closer look at these developments and what they mean, in a way that pushes back on narratives normalizing the...
